Triveni Bio Raises $115 Million Series B Financing to Expand Pipeline of Therapeutics Addressing Immunological and Inflammatory (I&I) Disorders
Press Release/10.2.2024
About us
We are pioneering a genetics-informed precision medicine approach to develop functional antibodies for the treatment of immunological and inflammatory (I&I) disorders.
Through our proprietary platform, we hunt for and derisk novel therapeutic targets with strong genetic rationale across diseases, predict and stratify patient subpopulations, and provide insights into disease mechanisms.
Leadership Team
Our experienced team is backed by an industry-leading board of directors, strategic advisors, and key opinion leaders.
- Leadership Team
- Board of Directors
- Key Advisors
- Investors
Careers and culture
We are committed to recruiting the best and brightest minds to our growing team to advance a novel and innovative pipeline of I&I therapies.
Together, we have the potential to address some of the most challenging diseases for which limited treatment options exist – through enabling exciting biological discoveries.
Interested in working with us? Browse job opportunities
News and media
Stay up to date with Triveni Bio.
- News
- Media
- Events
Triveni Bio Appoints Bhaskar Srivastava, M.D., Ph.D., as Chief Medical Officer, Announces Key Program Updates
Press Release/6.12.2024
Triveni Bio Welcomes Jeff Albers and Allison Luo to its Board of Directors
Press Release/12.13.2023
Triveni Bio Launches with $92 Million Series A Financing to Advance Genetics-Informed Precision Medicines for the Treatment of Immunological and Inflammatory (I&I) Disorders
Press Release/10.26.2023